人类表皮生长因子受体2阳性肿瘤靶向药物研究进展

doi:10.11904/j.issn.1002-3070.2016.03.015

摘要/Abstract

摘要： 人类表皮生长因子受体2(HER-2)是目前研究最为透彻的人类原癌基因之一。研究表明在人类乳腺癌、胃癌、卵巢癌及其它肿瘤中均存在HER-2过表达的现象,这种过表达使其成为药物研发中的理想靶点。与传统的化疗药物相比,靶向药物和抑制剂类药物,能更好地改善患者的预后,提高患者的生存率,安全性和有效性也更加明显。本文综述了HER-2阳性肿瘤靶向药物的研究现状及治疗进展,为HER-2相关药物开发和临床治疗提供有价值的参考。

关键词: 人类表皮生长因子受体2, 肿瘤发生, 靶向药物

Abstract: Human epidermal growth factor receptor 2(HER-2)is one of the most thoroughly studied human proto-oncogene.In previous studies,overexpression of HER-2 was observed in breast,ovarian,gastric,and many other cancers,as a result,which became the ideal target of drug development.Compared with traditional chemotherapy drugs,targeted drugs and inhibitors could better improve the patients prognosis and survival rate,as well as the safety and efficacy.This paper summarizes the research status of HER-2 positive tumors targeted drugs and treatment progress,which can provide useful references for HER-2 drug development and clinical treatment.

Key words: Human epidermal growth factor receptor2, Tumorigenesis, Targeted drug

中图分类号:

R730.54

汪霖综述, 孟祥宁审校. 人类表皮生长因子受体2阳性肿瘤靶向药物研究进展[J]. 实用肿瘤学杂志, 2016, 30(3): 266-270.

WANG Lin,MENG Xiangning. Research progress on targeted drugs of human epidermal growth factor receptor 2 positive tumours[J]. PRACTICAL ONCOLOGY JOURNAL, 2016, 30(3): 266-270.

参考文献

1 Boekhout AH,Beijnen JH,Schellens JH.Trastuzumab[J].Oncologist,2011,16(6):800-810.
2 Fuentes G,Scaltriti M,Baselga J,et al.Synergy between trastuzumab and pertuzumab for human epidermal growth factor 2(Her2)from colocalization:an in silico based mechanism[J].Breast Cancer Res,2011,13(3):1-9.
3 陈阵,李长征,王哲海.乳腺癌HER-2检测的临床意义[J].实用肿瘤学杂志,2004,18(2):157-160.
4 Verri E,Guglielmini P,Puntoni M,et al.HER-2/neu oncoprotein overexpression in epithelial ovarian cancer:evaluation of its prevalence and prognostic significance[J].Oncology,2005,27(3):505-512.
5 罗力亚,刘风玲.HER-2/neu在肿瘤中研究进展及抗HER-2/neu治疗[J].现代肿瘤医学,2011,19(12):2573-2576.
6 梁高照,汪清,倪泽称,等.HER-2在新疆地区前列腺增生、前列腺癌病变中的表达及意义[J].临床和实验医学杂志,2014,13(3):177-180.
7 Landi L,Cappuzzo F.HER-2 and lung cancer[J].Expert Rev Anticancer Ther,2013,13(10):1219-1228.
8 周志忠,林奎生,叶慧珍,等.HER-2/neu基因在肝癌高发区原发性肝癌表达和意义[J].国际检验医学杂志,2013,34(8):941-942.
9 Arya G,Vandana M,Acharya S,et al.Enhanced antiproliferative activity of Herceptin(HER-2)cojugated gemcitabine-loaded chitosan nanoparticle in pancreatic cancer therapy[J].Nanomdeicine,2011,7(6):859-870.
10 Li C,Liu DR,Ye LY,et al.HER-2 overexpression and survival in colorectal cancer:a meta-analysis[J].Zhejiang Univ Sci B,2014,15(6):582-589.
11 姜卫星.Ki-67在TNBC和HER-2过表达型乳腺癌中表达及临床预后分析[D].河北:河北医科大学,2014:42-53.
12 Chao WR,Lee MY,Lin WL,et al.HER-2 amplification and overexpression are significantly correlated in mucinous epithelial ovarian cancer[J].Hum Pathol,2014,45(4):810-816.
13 Roukos DH.Targeting gastric cancer with trastuzumab:new clinical practice and innovative developments to overcome resistance[J].Ann Surg Oncol,2010,17(1):14-17.
14 田慧,耿傲蕾,邓骥.联合运用化疗药物、疫苗和单克隆抗体进行抗癌治疗[J].中国药房,2010,38(21):3626-3629.
15 von Minckwitz G,du Bois A,Schmidt M,et al.Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer:a German breast group 26/breast international group 03-05 study[J].J Clin Oncol,2009,27(12):1999-2006.
16 Blackwell KL,Burstein HJ,Storniolo AM,et al.Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive,trastuzumab-refractory metastatic breast cancer[J].Journal of Clinical Oncology,2010,28(7):1124-1130.
17 Baselga J,Cortés J,Kim SB,et al.Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer[J].N Engl J Med,2012,366(14):109-119.
18 Baselga J,Gelmon KA,Verma S,et al.Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy[J].J Clin Oncol,2010,28(7):1138-1144.
19 郭婧昀.曲妥珠单抗对Her-2过表达乳腺癌细胞株mTOR信号通路的影响[D].广东:南方医科大学,2012:15-22.
20 Lang SA,Hackl C,Moser C,et al.Implication of RICTOR in the mTOR inhibitor-mediated induction of insulin-like growth factor-I receptor(IGF-IR)and human epidermal growth factor receptor-2(Her2)expression in gastrointestinal cancer cells[J].Biochimica Et Biophysica Acta Molecular Cell Research,2010,1803(4):435-442.
21 Miller TW,Forbes JT,Shah C,et al.Inhibition of mammalian target of rapamycin is required for optimal antitumor effect of her2 inhibitors against her2-overexpressing cancer cells[J].Clinical Cancer Research,2009,15(23):7266-7276.
22 Tabernero J,Rojo F,Calvo E,et al.Dose-and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus:a phase I tumor pharmacodynamic study in patients with advanced solid tumors[J].J Clin Oncol,2008,26(10):1603-1610.
23 叶荆,王蓓,陈建彬,等.PI3K/Akt/mTOR通路抑制剂依维莫司治疗晚期乳腺癌的研究进展[J].肿瘤,2015,35(2):221-224.
24 Falcon BL,Barr S,Gokhale PC,et al.Reduced VEGF production,angiogenesis,and vascular regrowth contribute to the antitumor properties of dual mTORC1/mTORC2 inhibitors[J].Cancer Res,2011,71(5):1573-1583.
25 Morrow PK,Wulf GM,Ensor J,et al.Phase I/II study of trastuzumab in combination with everolimus(RAD001)in patients with HER-2-overexpressing metastatic breast cancer who progressed on trastuzumab based therapy[J].J of Clin Oncol,2011,29(23):3126-3132.
26 Andre F,Campone M,O′Regan R,et al.Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab[J].J of Clin Oncol,2010,28(34):5110-5115.
27 Burris HA 3rd.Overcoming acquired resistance to anticancer therapy:focus on the PI3K/AKT/mTOR pathway[J].Cancer Chemother Pharmacol,2013,71(4):829-842.
28 曾敏,江泽飞.mTOR抑制剂依维莫司在乳腺癌治疗中的研究进展[J].癌症进展,2012,10(5):221-226.
29 Hurvitz SA,Dalenc F,Campone M,et al.A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER-2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy[J].Breast Cancer Res Treat,2013,141(3):437-446.
30 Shattuck DL,Miller JK,Carraway KL,et al.Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells[J].Cancer Res,2008,68(5):1471-1477.
31 Chen CT,Kim H,Liska D,et al.MET activation mediates resistance to Lapatinib inhibition of HER-2-amplified gastric cancer cells[J].Molecular Cancer Therapeutics,2012,11(3):660-669.
32 郭晓林,姜雅秋,王丹.幽门螺杆菌感染与C-myc基因和P53基因表达与胃癌的相关性研究[J].中国老年学杂志,2007,27(1):56-58.
33 Lennerz JK,Kwak EL,Ackerman A,et al.MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib[J].J of Clin Oncol,2011,29(36):4803-4810.
34 Kataoka Y,Mukohara T,Tomioka H,et al.Foretinib(GSK1363089),a multi-kinase inhibitor of MET and VEGFRs,inhibits growth of gastric cancer cell lines by blocking inter-receptor tyrosine kinase Networks[J].Investigational New Drugs,2012,30(4):1352-1360.
35 赵志刚,柳晓春,王秀娥,等.Hsp90分子抑制剂拮抗肿瘤耐药的研究进展[J].现代生物医学进展,2014,15(14):2967-2971.
36 孟帅,山广志,李卓荣.Hsp90抑制剂的研究进展[J].中国抗生素杂志,2011,36(4):241-248.
37 Pazo Cid RA,Antón A.Advanced HER-2-positive gastric cancer:Current and future targeted therapies[J].Oncology Hematology,2013,85(3):350-362.
38 Milani A,Sangiolo D,Montemurro F,et al.Active immunotherapy in HER-2 overexpressing breast cancer:current status and future perspectives[J].Ann Oncol,2013,24(7):1740-17408.
39 赵丽丽,姜北海,寿成超.HER-2/neu肿瘤疫苗的研究进展[J].中国肿瘤生物治疗杂志,2010,17(2):221-226.

[1]	王大权综述, 赵路军, 王平审校. Wnt信号通路与非小细胞肺癌发生发展关系的研究进展[J]. 实用肿瘤学杂志, 2016, 30(1): 66-70.
[2]	彭芳, 陈明. 放疗联合分子靶向药物治疗非小细胞肺癌的研究进展[J]. 实用肿瘤学杂志, 2012, 26(1): 42-48.
[3]	孟凡婷, 韩世愈. miRNA与卵巢癌[J]. 实用肿瘤学杂志, 2011, 25(6): 571-574.
[4]	孙婷婷, 白玉贤. 胃癌的分子靶向治疗[J]. 实用肿瘤学杂志, 2011, 25(2): 190-193.
[5]	叶小红, 张沂平. 非小细胞肺癌常见靶向药物的毒副反应研究进展[J]. 实用肿瘤学杂志, 2010, 24(2): 182-185.
[6]	姜明哲综述, 李晓莉审校. 乳腺癌的靶向治疗[J]. 实用肿瘤学杂志, 2008, 22(6): 586-589.